Vanguard Global Advisers
OCUL icon

Vanguard Global Advisers’s Ocular Therapeutix OCUL Stock Holding History

Vanguard Global Advisers’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$651K Sell
66,273
-4,634
-7% -$42K ﹤0.01% 1982
2026
Q1 		$601K Buy
+70,907
New +$676K ﹤0.01% 1952

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's OCUL Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Ocular Therapeutix (OCUL) stake by 6.5% in Q2 2026, selling an estimated $42K and leaving 66,273 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Vanguard Global Advisers first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 259 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Vanguard Global Advisers held 66,273 shares of Ocular Therapeutix worth $651K as of Q2 2026.
  • Vanguard Global Advisers sold 4,634 Ocular Therapeutix shares in Q2 2026, an estimated $42K.
  • Ocular Therapeutix made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1982 holding.
  • Vanguard Global Advisers first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
  • 259 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.